Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Abstract Introduction Risankizumab (RZB) and deucravacitinib (DEU) are both approved for the treatment of moderate-to-severe psoriasis. Physicians value head-to-head comparisons between available therapies to make evidence-based treatment decisions. This study evaluates the safety and efficacy of RZ...

詳細記述

書誌詳細

主要な著者:	Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren
フォーマット:	Artigo
言語:	Inglês
出版事項:	Adis, Springer Healthcare 2026-05-01
シリーズ:	Dermatology and Therapy
主題:	Moderate psoriasis Risankizumab Systemic therapy Biologics
オンライン･アクセス:	https://doi.org/10.1007/s13555-026-01779-x
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!